Kaplan Fox is Investigating Possible Securities Law Violations Against Corcept Therapeutics, Inc. (CORT)
Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Corcept Therapeutics, Inc. following two significant drops in stock price. The first drop of over 50% occurred on December 31, 2025, after Corcept announced a Complete Response Letter from the FDA regarding its New Drug Application for relacorilant. A further 12% decline happened on January 30, 2025 (corrected to 2026), after a more detailed, corrected FDA letter, which criticized Corcept's clinical development program, was disseminated.
Investor Alert: Robbins LLP Informs Investors of the Corcept Therapeutics Inc. Class Action Lawsuit
Robbins LLP is informing investors of a class action lawsuit against Corcept Therapeutics Inc. (NASDAQ: CORT) for allegedly misleading investors about its new product candidate, relacorilant. The company's stock price declined significantly after the FDA issued a Complete Response Letter for relacorilant's New Drug Application due to concerns about effectiveness. Investors who purchased Corcept stock between October 31, 2024, and December 30, 2025, may be eligible to participate in the lawsuit.
INVESTOR ALERT: Corcept Therapeutics Incorporated Investors with Substantial Losses Have Opportunity to Lead the Corcept Class Action Lawsuit – RGRD Law
Robbins Geller Rudman & Dowd LLP has announced a class action lawsuit against Corcept Therapeutics Incorporated (NASDAQ: CORT) on behalf of investors who purchased common stock between October 31, 2024, and December 30, 2025. The lawsuit alleges that Corcept misrepresented the likelihood of FDA approval for its lead product candidate, relacorilant, concealing repeated FDA concerns about the adequacy of clinical evidence. After the FDA issued a Complete Response Letter detailing these concerns, Corcept's stock price dropped by more than 50%.
Investor Alert: Robbins LLP Informs Investors of the Corcept Therapeutics Inc. Class Action Lawsuit
Robbins LLP has announced a class action lawsuit filed against Corcept Therapeutics Inc. on behalf of investors who purchased common stock between October 31, 2024, and December 30, 2025. The lawsuit alleges that Corcept misled investors regarding the viability of its new product candidate, relacorilant, leading to a significant stock price drop after the FDA issued a Complete Response Letter. Shareholders are encouraged to contact Robbins LLP if they wish to participate or learn more about the lawsuit.
Corcept Therapeutics (NASDAQ:CORT) Price Target Lowered to $67.00 at HC Wainwright
HC Wainwright has lowered its price target for Corcept Therapeutics (NASDAQ:CORT) to $67.00 from $105.00, while maintaining a "buy" rating. This adjustment follows a U.S. Court of Appeals decision that Teva's proposed generic for Korlym does not infringe on two patents, leading to a significant stock selloff and increased downside risk for Corcept. The article also notes substantial insider selling of CORT shares in the last three months.
Jupiter Asset Management Ltd. Has $29.17 Million Holdings in Corcept Therapeutics Incorporated $CORT
Jupiter Asset Management Ltd. significantly reduced its stake in Corcept Therapeutics, selling 41.6% of its shares in Q3, now holding 350,929 shares valued at $29.17 million. This divestment comes amid multiple negative factors impacting Corcept, including an appellate court ruling favoring a generic competitor for its drug Korlym, creating a legal and regulatory overhang. Insider selling and a prior FDA Complete Response Letter for another drug candidate further contribute to investor uncertainty, despite the company's strong balance sheet.
Corcept Therapeutics Loses Cushing's Syndrome Patent Case Against Teva
Corcept Therapeutics announced it lost a patent infringement case against Teva Pharmaceuticals regarding its Cushing's syndrome drug, Korlym. A U.S. court ruled that Teva's generic version of Korlym does not infringe on Corcept's patents. This news comes shortly after Corcept reported positive results from a different trial for its ovarian cancer drug, relacorilant.
CORT (-14%): Korlym Patent Defeat Unlocks Generic Threat
The article discusses the patent defeat of Korlym, a drug produced by CORT, which has led to a significant 14% drop in the company's stock value. This defeat opens the door for generic competition, posing a threat to CORT's market position. The content itself seems to be a placeholder or incomplete, focusing more on Trefis platform details than the actual financial implications of the patent defeat.
Corcept Provides Update on Patent Dispute with Teva Pharmaceuticals
Corcept Therapeutics announced that the U.S. Court of Appeals for the Federal Circuit affirmed a lower court's ruling that Teva Pharmaceuticals' generic version of Korlym does not infringe on two of Corcept's patents. These patents relate to methods of safely co-administering Korlym with CYP3A4 inhibiting drugs, which are commonly prescribed to Cushing's syndrome patients. Corcept expressed disappointment in the decision and stated its intent to vigorously defend its rights and pursue further judicial review.
CORT ALERT: Kaplan Fox & Kilsheimer LLP is Investigating Corcept
Kaplan Fox & Kilsheimer LLP is investigating Corcept Therapeutics, Inc. (CORT) for potential securities law violations after the company's stock dropped significantly following negative news regarding its New Drug Application (NDA) for relacorilant. The FDA issued a Complete Response Letter due to concerns about the drug's effectiveness and the adequacy of Corcept's clinical development program. Investors who suffered losses are encouraged to contact Kaplan Fox for more information on the investigation.
Teva wins appeal in fight over generic version of Cushing’s drug
Corcept Therapeutics announced that the United States Court of Appeals for the Federal Circuit affirmed a December 2023 verdict, ruling that Teva Pharmaceuticals' generic version of Korlym does not infringe on two of Corcept's patents. These patents relate to methods of safely co-administering Korlym with CYP3A4 enzyme-inhibiting drugs. Corcept expressed disappointment in the ruling and stated its intent to vigorously defend its intellectual property rights.
Corcept Therapeutics Down 21%: Why Is CORT Stock Crashing Today?
Corcept Therapeutics (CORT) shares plummeted 21% after a U.S. appeals court upheld a non-infringement ruling in favor of Teva Pharmaceuticals regarding a patent dispute over Corcept's drug Korlym. The case dates back to 2018, with Corcept alleging patent infringement related to its medication for Cushing syndrome. Despite the setback, analysts currently hold a Moderate Buy consensus rating for CORT, with a significant implied growth potential.
Corcept Therapeutics stock hits 52-week low at 32.63 USD
Corcept Therapeutics (CORT) stock has fallen to a new 52-week low of $32.63, reflecting a significant year-long decline of 45.85%. Despite this downturn, the company shows strong fundamentals with a high gross profit margin and revenue growth, and its stock is considered undervalued by InvestingPro. This follows positive Phase 3 trial results for its ovarian cancer drug, which analysts believe could significantly improve its prospects.
Corcept Therapeutics stock falls after losing key patent case appeal By Investing.com
Corcept Therapeutics' stock plummeted 25% after the U.S. Court of Appeals for the Federal Circuit ruled that Teva Pharmaceuticals did not infringe on Corcept's patents related to its drug Korlym. This decision, which found "no infringement" concerning methods of safely administering Korlym, represents a major legal setback for Corcept. The ruling could pave the way for Teva to produce generic versions of Korlym, potentially impacting Corcept's revenue and market exclusivity.
Corcept Therapeutics Stock Plunges As Court Clears Teva Generic
Corcept Therapeutics Inc. (NASDAQ: CORT) shares plummeted after the U.S. Court of Appeals for the Federal Circuit affirmed a lower court's decision, clearing Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) to produce a generic version of Korlym. This ruling removes a significant legal barrier for Teva, increasing the risk of competition for Corcept's flagship drug used to treat Cushing's syndrome. The decision heightens market uncertainty around Korlym's revenue durability and pressures Corcept to diversify its portfolio, especially with an earnings report due on February 24th.
CORT SECURITIES INVESTIGATION: Kaplan Fox Reminds Investors of Corcept Therapeutics, Inc. (CORT) to an Investigation of Potential Securities Law Violations
Kaplan Fox & Kilsheimer LLP is investigating potential securities law violations against Corcept Therapeutics, Inc. (CORT) following a significant decline in its stock price. The investigation stems from the FDA issuing a Complete Response Letter for relacorilant, citing concerns about its effectiveness, which caused CORT shares to drop over 50%. A corrected CRL further revealed the FDA had repeatedly expressed concerns regarding the clinical development program, leading to another stock decline.
Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results, Provide Corporate Update and Host Conference Call
Corcept Therapeutics (NASDAQ: CORT) announced it will report its fourth quarter and full-year 2025 financial results and provide a corporate update on February 24, 2026. The company will host a conference call on that day at 5:00 p.m. Eastern Time, and participants need to register in advance. A listen-only webcast will also be available, and a replay will be posted on Corcept.com.
Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results, Provide Corporate Update and Host Conference Call
Corcept Therapeutics (NASDAQ: CORT) announced it will report its fourth quarter and full-year 2025 financial results and provide a corporate update on February 24, 2026. The company will also host a conference call at 5:00 p.m. Eastern Time on the same day. Interested participants must register in advance for the call, and a listen-only webcast will also be available.
CORT SECURITIES INVESTIGATION: Kaplan Fox Reminds Investors of Corcept Therapeutics, Inc. (CORT) to an Investigation of Potential Securities Law Violations
Kaplan Fox & Kilsheimer LLP is investigating potential securities law violations by Corcept Therapeutics, Inc. (NASDAQ: CORT). The investigation follows a significant drop in Corcept's stock price after the FDA issued a Complete Response Letter regarding their New Drug Application for relacorilant, citing concerns about effectiveness and the clinical development program. Kaplan Fox is encouraging investors who suffered losses to contact them for more information.
Corcept earnings up next: Can Korlym bridge to cancer opportunity? By Investing.com
Corcept Therapeutics is set to release its Q4 and full-year 2025 results, with investors focusing on the sustainability of its Korlym franchise and the potential impact of a regulatory decision for its ovarian cancer drug, relacorilant. Despite a previous regulatory setback for relacorilant in Cushing's syndrome, analysts are optimistic due to positive Phase 3 trial results in ovarian cancer and rising EPS estimates. The company's ability to overcome operational challenges and pivot towards new growth opportunities will be key to its future performance.
CORCEPT THERAPEUTICS INCORPORATED (NASDAQ: CORT) INVESTIGATION ALERT: Bernstein Liebhard is Investigating Possible Securities Claims against Corcept Therapeutics Incorporated
Bernstein Liebhard LLP is investigating Corcept Therapeutics Incorporated (NASDAQ: CORT) for potential federal securities law violations. This follows a significant 50.42% stock price drop on December 31, 2025, after the FDA issued a Complete Response Letter for relacorilant's New Drug Application, citing a lack of sufficient evidence for effectiveness despite the primary endpoint being met in the GRACE trial. The law firm is seeking to represent investors who lost money in their Corcept stock.
Corcept Therapeutics Inc (NASDAQ:CORT) Presents a Compelling GARP Investment Case
Corcept Therapeutics Inc. (NASDAQ:CORT) is highlighted as a compelling "Growth at a Reasonable Price" (GARP) investment. The company exhibits strong growth potential with projected EPS and sales increases, coupled with robust profit margins and a very strong financial position, including no debt. While its P/E ratio appears high in isolation, it is more favorable when compared to pharmaceutical industry peers, making it an attractive option for investors seeking balanced growth and value.
FDA-Issued CRL for Relacorilant NDA Leads to Bullish Views Around Corcept Therapeutics (CORT)
Despite the FDA issuing a Complete Response Letter (CRL) for Relacorilant's NDA, analysts are maintaining bullish views on Corcept Therapeutics (CORT). Canaccord Genuity reaffirmed a Buy rating with a $100 price target, and H.C. Wainwright raised its price target to $105, both factoring in the need for additional trials and strong survival data from the ROSELLA study for ovarian cancer. Corcept Therapeutics is a pharmaceutical company developing therapies for various severe conditions including endocrinologic, oncologic, metabolic, and neurologic disorders.
CORT ALERT: Ongoing Investigation Into Corcept Therapeutics Incorporated - Contact Levi & Korsinsky
Levi & Korsinsky has initiated an investigation into Corcept Therapeutics Incorporated (NASDAQ: CORT) following a significant drop in its stock price. This decline occurred after the FDA denied approval for Corcept's drug relacorilant, citing insufficient evidence of effectiveness. The firm is inviting investors who suffered losses to explore potential recovery options.
CORT INVESTIGATION REMINDER: Corcept Therapeutics Faces Potential Securities Law Violations - Contact Kaplan Fox & Kilsheimer LLP
Kaplan Fox & Kilsheimer LLP is investigating potential securities law violations by Corcept Therapeutics, Inc. (NASDAQ: CORT) following two significant stock drops. The first occurred after the FDA issued a Complete Response Letter for relacorilant, citing insufficient evidence of effectiveness, causing a 50% stock decline. A subsequent correction to the CRL revealed the FDA had previously warned Corcept about the inadequacy of its clinical program, leading to another 12% drop.
CORCEPT THERAPEUTICS SECURITIES INVESTIGATION: Kaplan Fox Alerts Investors of Corcept Therapeutics, Inc. (CORT) to an Investigation of Possible Securities Law Violations
Kaplan Fox & Kilsheimer LLP is investigating Corcept Therapeutics, Inc. (CORT) for potential securities law violations after two significant stock declines. The declines followed a Complete Response Letter from the FDA regarding relacorilant's New Drug Application due to insufficient evidence of effectiveness, and later, a corrected CRL indicating the FDA had previously warned Corcept about its clinical development program. Investors who suffered losses are encouraged to contact Kaplan Fox for more information on the investigation.
CORT INVESTIGATION REMINDER: Corcept Therapeutics Faces Potential Securities Law Violations - Contact Kaplan Fox & Kilsheimer LLP
Kaplan Fox & Kilsheimer LLP is investigating potential securities law violations by Corcept Therapeutics, Inc. (NASDAQ: CORT). This investigation follows a significant drop in Corcept's stock price after the FDA issued a Complete Response Letter for its new drug application, citing concerns about the drug's effectiveness. Further stock declines occurred when a corrected version of the FDA's letter, highlighting prior warnings to Corcept, was disseminated.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Incorporated - CORT
Pomerantz LLP is investigating potential securities fraud claims against Corcept Therapeutics Incorporated following a significant drop in its stock price. The investigation comes after the FDA issued a Complete Response Letter for Corcept's new drug application for relacorilant, citing a need for additional evidence of effectiveness despite trials meeting primary endpoints. Investors are advised to contact Pomerantz LLP for information regarding joining a potential class action.
Options Exercise: Hazel Hunt At Corcept Therapeutics Realizes $5.53M
Hazel Hunt, Chief Scientific Officer at Corcept Therapeutics (NASDAQ: CORT), exercised stock options totaling 150,000 shares, valued at $5.53 million. The company, a commercial-stage pharmaceutical firm, is developing medications for severe metabolic, oncologic, and neuropsychiatric disorders. The article also details Corcept Therapeutics's financial performance, including revenue growth, gross margin, EPS, debt management, and various valuation metrics.
CORCEPT THERAPEUTICS INCORPORATED (NASDAQ: CORT)
Bernstein Liebhard LLP is investigating Corcept Therapeutics Incorporated (NASDAQ: CORT) for potential federal securities law violations after the company's stock price dropped significantly. This follows the FDA issuing a Complete Response Letter for relacorilant's New Drug Application, citing a lack of sufficient evidence for a favorable benefit-risk assessment despite positive trial results. Investors who lost money are encouraged to contact Bernstein Liebhard for a discussion of their legal rights.
CORCEPT THERAPEUTICS Investors Are Encouraged to Contact Kaplan Fox & Kilsheimer LLP Regarding Potential Securities Law Violations
Kaplan Fox & Kilsheimer LLP is investigating Corcept Therapeutics, Inc. (NASDAQ: CORT) for potential securities violations after the company received a Complete Response Letter from the FDA for its new drug application for relacorilant, causing a significant stock price drop. Further declines occurred following the dissemination of a corrected CRL revealing that the FDA had previously warned Corcept about the adequacy of its clinical development program. Investors who suffered losses or have relevant information are encouraged to contact Kaplan Fox.
CORCEPT THERAPEUTICS INVESTIGATION ALERT: Corcept Therapeutics Faces Potential Securities Law Violations - Contact Kaplan Fox & Kilsheimer LLP
Kaplan Fox & Kilsheimer LLP is investigating potential securities law violations against Corcept Therapeutics, Inc. following two significant stock declines. The declines occurred after the FDA issued a Complete Response Letter for relacorilant, citing concerns about the clinical development program's adequacy, subsequently leading to a over 50% stock drop. A corrected version of the CRL further emphasized the FDA's prior warnings, causing another 12% intraday stock decline.
Corcept Therapeutics Faces Potential Securities Law Violations - Contact Kaplan Fox & Kilsheimer LLP
Kaplan Fox & Kilsheimer LLP is investigating Corcept Therapeutics, Inc. (NASDAQ: CORT) for potential securities law violations after the FDA issued a Complete Response Letter (CRL) for its new drug application relacorilant. The CRL, which cited concerns about the drug's effectiveness, caused Corcept's stock to drop over 50% in December 2025 and an additional 12% in January 2026 after a corrected CRL was disseminated. The firm encourages affected investors to contact them for more information regarding the investigation.
CORCEPT THERAPEUTICS INCORPORATED (NASDAQ: CORT)
Bernstein Liebhard LLP is investigating Corcept Therapeutics Incorporated (NASDAQ: CORT) for possible securities law violations after the FDA issued a Complete Response Letter for relacorilant due to insufficient evidence of effectiveness, causing a significant stock price drop. The firm is inviting investors who lost money to discuss their legal rights and options regarding this investigation.
CORT INVESTIGATION ALERT: Investigation Launched into Corcept Therapeutics (CORT), Hagens Berman Encourages Investors to Contact Firm
Hagens Berman has launched an investigation into Corcept Therapeutics (CORT) following a significant drop in its stock price. This decline occurred after the FDA issued a complete response letter for its hypercortisolism drug, relacorilant, and subsequently revealed that it had warned Corcept against submitting its application multiple times. The firm is investigating whether Corcept misled investors about relacorilant's efficacy, commercial prospects, and communications with the FDA.
CORT shares plummet on FDA’s drug rejection letter reveal — here’s what retail has to say
Shares of CORT (Corcept Therapeutics) have significantly dropped after the FDA revealed its rejection letter for the company's drug, relacorilant. This news has led to concerned discussions among retail investors regarding the future of the stock and the implications for the company's financial health and drug pipeline. The market reaction indicates strong investor disappointment following the regulatory setback.
CORT SECURITIES INVESTIGATION: Kaplan Fox is Investigating Possible Securities Violations Against Corcept Therapeutics, Inc. (CORT)
Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Corcept Therapeutics, Inc. (CORT) after the company received a Complete Response Letter (CRL) from the FDA for its New Drug Application for relacorilant, leading to a significant stock price decline. The FDA cited concerns over the adequacy of the clinical development program and effectiveness assessment for relacorilant. Kaplan Fox is encouraging affected investors to contact them for more information.
CORT SECURITIES INVESTIGATION: Kaplan Fox is Investigating Possible Securities Violations Against Corcept Therapeutics, Inc. (CORT)
Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Corcept Therapeutics, Inc. (CORT) following two significant stock drops. The investigation stems from the FDA issuing a Complete Response Letter for Corcept's drug relacorilant, citing insufficient evidence of effectiveness, leading to a 50% stock decline. Further concerns from a corrected CRL regarding the adequacy of Corcept's clinical development program caused another 12% drop in stock price.
CORCEPT THERAPEUTICS Is Being Investigated for Potential Securities Law Violations - Contact Kaplan Fox & Kilsheimer LLP
Kaplan Fox & Kilsheimer LLP is investigating Corcept Therapeutics, Inc. (NASDAQ: CORT) for potential securities law violations after the company's stock price dropped significantly following two announcements regarding its New Drug Application (NDA) for relacorilant. The FDA issued a Complete Response Letter, citing concerns about the drug's effectiveness, leading to over 50% decline in stock value on December 31, 2025, and an additional 12% drop on January 30, 2025, after a corrected CRL was disseminated. The firm is seeking investors who suffered losses to join the investigation.
Is Corcept Therapeutics (CORT) Price Weakness Creating A Long Term Opportunity?
Corcept Therapeutics (CORT) has experienced significant share price volatility, with a 43.6% decline over the past year. Despite this, a Discounted Cash Flow (DCF) analysis suggests the stock could be undervalued by 88.3%, estimating an intrinsic value of $328.66 per share compared to its current price of $38.36. The company's P/E ratio also sits below Simply Wall St's proprietary Fair Ratio, further suggesting a potential discount.
Insider Sell: William Guyer Sells 20,000 Shares of Corcept Thera
William Guyer, Chief Development Officer at Corcept Therapeutics Inc (CORT), sold 20,000 shares of the company on February 3, 2026. This transaction reduces his total holdings to 1,235 shares. The stock is considered modestly undervalued with a price-to-GF-Value ratio of 0.79, despite a P/E ratio higher than both the industry median and its historical median.
CORCEPT THERAPEUTICS INCORPORATED (NASDAQ: CORT) INVESTIGATION ALERT: Bernstein Liebhard is Investigating Possible Securities Claims against Corcept Therapeutics Incorporated
Bernstein Liebhard LLP is investigating Corcept Therapeutics Incorporated (NASDAQ: CORT) for possible federal securities law violations after the company's stock price dropped significantly. This occurred after the FDA issued a Complete Response Letter for relacorilant, citing insufficient evidence of effectiveness, despite acknowledging the primary endpoint was met in a key trial. The firm is inviting investors who lost money to discuss their legal rights and options.
Despite lower earnings than three years ago, Corcept Therapeutics (NASDAQ:CORT) investors are up 71% since then
Corcept Therapeutics (NASDAQ:CORT) shareholders have seen a 71% return over the past three years, despite a recent 45% drop in share price over three months and a 2.7% annual decline in EPS during the same three-year period. The article suggests that the 24% revenue growth rate over three years might be a key factor in investor confidence, indicating a focus on growth over immediate earnings. It also notes that while the broader market gained 14% last year, CORT shareholders lost 41%, but longer-term investors still saw an average 6% annual return over five years.
CORCEPT THERAPEUTICS SECURITIES INVESTIGATION: Kaplan Fox & Kilsheimer LLP is Investigating Corcept Therapeutics, Inc. (CORT) for Possible Securities Law Violations
Kaplan Fox & Kilsheimer LLP is investigating Corcept Therapeutics, Inc. (CORT) for potential securities law violations after the company's stock price significantly dropped following two announcements. The first drop occurred when the FDA issued a Complete Response Letter (CRL) for relacorilant, citing a lack of sufficient evidence for effectiveness. A subsequent dissemination of a corrected CRL further detailing the FDA's long-standing concerns led to another decline in Corcept's stock.
CORCEPT THERAPEUTICS INCORPORATED (NASDAQ: CORT) INVESTIGATION ALERT: Bernstein Liebhard is Investigating Possible Securities Claims against Corcept Therapeutics Incorporated
Bernstein Liebhard LLP is investigating potential securities claims against Corcept Therapeutics Incorporated (NASDAQ: CORT) following a significant stock price drop. The investigation comes after the FDA issued a Complete Response Letter for Corcept's New Drug Application for relacorilant, citing a need for additional effectiveness evidence. Corcept's stock fell over 50% on the news, leading the firm to seek out affected investors.
CORT Investors Have Opportunity to Join Corcept Therapeutics Incorporated Fraud Investigation with the Schall Law Firm
The Schall Law Firm is investigating Corcept Therapeutics Incorporated (NASDAQ: CORT) on behalf of investors for potential securities law violations. This investigation follows Corcept's announcement on December 31, 2025, that the FDA issued a Complete Response Letter for its relacorilant NDA, citing a lack of sufficient evidence for a favorable benefit-risk assessment despite the drug meeting its primary endpoint in the GRACE trial. This news led to a more than 50% drop in Corcept's stock price.
CORCEPT INVESTIGATION ALERT: Bragar Eagel & Squire, P.C.
Bragar Eagel & Squire, P.C., a stockholder rights law firm, is investigating potential claims against Corcept Therapeutics Incorporated (NASDAQ:CORT) after the FDA issued a Complete Response Letter for its new drug application, causing Corcept's stock price to fall significantly. The firm is encouraging Corcept stockholders who suffered losses to contact them to discuss their legal rights. This investigation focuses on whether Corcept violated federal securities laws or engaged in unlawful business practices.
CORCEPT INVESTIGATION ALERT: Bragar Eagel & Squire, P.C.
Bragar Eagel & Squire, P.C. is investigating potential claims against Corcept Therapeutics Incorporated (NASDAQ: CORT) on behalf of its stockholders. This investigation follows a significant 50.42% drop in Corcept's stock price after the FDA issued a Complete Response Letter for its new drug application for relacorilant, citing a need for additional evidence of effectiveness despite positive trial data. The law firm is encouraging investors who suffered losses to contact them to discuss their legal options.
Lost Money on Corcept Therapeutics Incorporated (CORT)? Possible Fraud - Contact Levi & Korsinsky Today
Levi & Korsinsky has initiated an investigation into Corcept Therapeutics (NASDAQ: CORT) regarding potential federal securities law violations. This follows a significant stock price drop on December 31, 2025, after the FDA denied approval for Corcept's drug relacorilant for hypertension due to insufficient evidence of effectiveness, causing CORT shares to fall by 44.76% and hit a new 52-week low. The firm is encouraging investors who suffered losses to contact them for a potential recovery.
Securities Fraud Investigation Into Corcept Therapeutics Incorporated (CORT) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
Glancy Prongay Wolke & Rotter LLP has launched a securities fraud investigation into Corcept Therapeutics Incorporated (CORT) following two significant stock price drops. The investigation stems from the FDA's decision to decline approval for Corcept's relacorilant NDA, citing concerns about the adequacy of the clinical development program. Shareholders who lost money are encouraged to contact the firm for potential claims.
